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Abstract
Polysialic acid (polySia), an α-2,8-glycosidically linked polymer of sialic acid, is a developmentally regulated post-
translational modification predominantly found on NCAM (neuronal cell adhesion molecule). Whilst high levels are
expressed during development, peripheral adult organs do not express polySia-NCAM. However, tumours of neural
crest-origin re-express polySia-NCAM: its occurrence correlates with aggressive and invasive disease and poor
clinical prognosis in different cancer types, notably including small cell lung cancer (SCLC), pancreatic cancer and
neuroblastoma. In neuronal development, polySia-NCAM biosynthesis is catalysed by two polysialyltransferases,
ST8SiaII and ST8SiaIV, but it is ST8SiaII that is the prominent enzyme in tumours. The aim of this study was to
determine the effect of ST8SiaII inhibition by a small molecule on tumour cell migration, utilising cytidine
monophosphate (CMP) as a tool compound. Using immunoblotting we showed that CMP reduced ST8iaII-mediated
polysialylation of NCAM. Utilizing a novel HPLC-based assay to quantify polysialylation of a fluorescent acceptor
(DMB-DP3), we demonstrated that CMP is a competitive inhibitor of ST8SiaII (Ki = 10 µM). Importantly, we have
shown that CMP causes a concentration-dependent reduction in tumour cell-surface polySia expression, with an
absence of toxicity. When ST8SiaII-expressing tumour cells (SH-SY5Y and C6-STX) were evaluated in 2D cell
migration assays, ST8SiaII inhibition led to significant reductions in migration, while CMP had no effect on cells not
expressing ST8SiaII (DLD-1 and C6-WT). The study demonstrates for the first time that a polysialyltransferase
inhibitor can modulate migration in ST8SiaII-expressing tumour cells. We conclude that ST8SiaII can be considered a
druggable target with the potential for interfering with a critical mechanism in tumour cell dissemination in metastatic
cancers.
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Introduction
Whilst crucial in the course of normal development and cell
differentiation [1], abnormalities in the presentation of cell-
surface carbohydrates are strongly associated with cancer
progression and metastasis [2,3]. The vast range of
glycosylation possibilities in the glycocalyx provides the tumour
cell with an extensive resource for altering the nature and
extent of its interactions with the local environment [4].
Simultaneously, the recognition and exploitation of enzymes
responsible for the biosynthesis of tumour specific
glycoconjugates involved in metastatic progression offers a
large, though significantly underexplored therapeutic
opportunity [5,6].
PolySia has long been recognised to be essential in steering
cellular interactions during neuronal development [7,8]. PolySia
is a homopolymer of N-acetylneuraminic acid (sialic acid,
Neu5Ac), linked specifically via α-2,8-glycosidic bonds, and is
negatively charged at physiological pH. The major polySia-
carrier is the neural cell adhesion molecule (NCAM) [9] and
addition of polySia to NCAM crucially impacts neuronal
development [10]. PolySia attenuates NCAM-mediated
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interactions, resulting in conditions permissive for changes in
cell position or shape [11]. Attachment of the polyanionic
polySia to NCAM doubles the hydrodynamic radius of its
extracellular part, thereby increasing the inter-membrane
space. This disrupts the adhesive properties of NCAM and
other cell adhesion molecules [12].
Biosynthesis of polySia is effected by two
polysialyltransferases (polySTs): ST8SiaII and ST8SiaIV [13]
and these two enzymes are independently able to transfer
multiple Neu5Ac residues in α-2,8-linkages to acceptor N-
glycans on NCAM. Evidence clearly demonstrates that
polysialylation is a protein-specific reaction in which the
polySTs initially recognise sequences on NCAM prior to
effecting glycan modifications [14–17]. The polySTs show
independent but overlapping expression patterns [18–20], with
ST8SiaII being the prominent enzyme in embryonic
development [19,21]. From heavy NCAM polysialylation during
the initial stages of the perinatal and early postnatal phases,
polySia levels drop dramatically soon afterwards [20,22]. By
this stage, polySia is essentially absent from the body [20].
Expression in the adult, at considerably lower levels, appears
confined to limited brain regions of persistent neural plasticity,
where ST8SiaIV is the major enzyme [18,19,22,23].
Conversely, it is ST8SiaII that is the major driver of
polysialylation in tumour cells [24], where re-expression of
polySia drives metastatic behaviour in cancer [6]. ST8SiaII is
thus an attractive anti-tumour target.
PolySia-expressing cancers include small cell lung cancer,
neuroblastoma, pancreatic cancer, pituitary tumours, glioma
and Wilms’ tumour (for a review, see Falconer et al. 2012) [6].
PolySia is strongly expressed in cancer cell lines [25–30],
promotes tumour cell migration in vitro [31] and affects tumour
cell differentiation by attenuating NCAM signalling [32]. In vivo
studies indicate that polySia-NCAM expression is closely
associated with tumour invasion and metastasis, as
demonstrated with neuroblastoma [30], lung cancer [33,34],
pituitary cancer [35] and glioma [36] models. The role of
polySia-NCAM as a key regulator of tumour cell migration was
demonstrated in neuroblastoma cells in vitro [37] and both
siRNA knock-down of ST8SiaII and enzymatic removal of
polySia by endoneuraminidase (EndoN, which specifically
removes polySia from NCAM) both independently lead to
abolition of cell migration in tumour cells [38]. However, it is
only more recently that the molecular mechanisms
underpinning the role of polySia in tumour dissemination are
being understood [6,37].
The evidence for the importance of polySia in tumour
dissemination of those cancers where it is expressed is now
compelling. Thus far, pharmacological interrogation of this
interesting target has been limited by a paucity of polyST
inhibitors. Sialic acid precursor molecules (e.g. N-
butanoylmannosamine) have been reported, but whether they
inhibit polySTs through conversion to the corresponding
modified CMP-Neu5Ac in the cell [39–41] or lead to de novo
biosynthesis of modified polySia remains unclear [42,43]. We
previously reported small molecule inhibitors based on CMP
[44]. However, a pharmacological link between polyST
inhibition, polySia biosynthesis and tumour dissemination
remains to be established. In this study we use CMP as a
prototype small molecule polyST inhibitor and show for the first
time a correlation between inhibition of ST8SiaII and tumour
cell migration.
Materials and Methods
Materials
All general chemicals, media and media supplements were
obtained from Sigma-Aldrich (Poole, UK) unless otherwise
specified. DMB-DP3 was synthesised as previously described
[45]. Rabbit anti-NCAM polyclonal antibody (AB5032) which
recognises all NCAM isoforms was purchased from Chemicon-
Millipore (Watford, UK). Anti polySia-NCAM monoclonal
antibody (mAb735) [46] was used after purification on Protein
A-Sepharose (Amersham Pharmacia Biotech). EndoNA2-eGFP
was kindly donated by Prof. Jukka Finne (University of Helsinki,
Helsinki, Finland). EndoN was obtained from Abcys (Paris,
France). Human recombinant ST8SiaII was synthesised in
collaboration with Dr Edward McKenzie (University of
Manchester).
Cell lines
IMR32, SH-SY5Y and DLD-1 cells were obtained from ATCC
(Manassas, USA). IMR32 and SH-SY5Y cells were maintained
in Minimum Essential Medium (MEM) supplemented with
Foetal Calf Serum (FCS, 10%), L-glutamine (2 mM), and
sodium pyruvate (1 mM). DLD-1 was maintained in Roswell
Park Memorial Institute (RPMI) 1640 medium supplemented
with FCS (10%), L-glutamine (2 mM), and sodium pyruvate (1
mM). The C6-STX and C6-WT glioma cell lines [36] were
grown in alpha MEM medium (VWR, Leicestershire, UK)
supplemented with FCS (10%).
Measurement of ST8SiaII inhibition
ST8SiaII activity was determined under the following
conditions: MES (50 mM, pH 7.0), MgCl2 (5 mM), CMPNeu5Ac
(500 µM), ST8SiaII (250 ng), and varying amounts of DMB-
DP3 were incubated at 25° C for the indicated times. The
reactions were terminated by 10-fold dilution in Tris–HCl (100
mM, pH 8.0) / ethylenediamine-tetraacetic acid (EDTA, 20 mM)
followed by 10 min incubation at 50° C. Finally, the samples
were centrifuged at 20,000 g for 10 min at 4° C before
analysing on a DNAPAC PA 100 analytical anion exchange
column (Ex. 373 nm/Em. 448 nm). The buffer system used
was: mobile phase A: H2O; mobile phase B: 5.0 M ammonium
acetate buffer (pH 7.4). HPLC was carried out using a Waters
2695 Separations Module connected to an RF-10A
spectrofluorometric detector at a flow rate of 1 mL min-1. To
determine the Ki for CMP, the reaction was carried out as
above except with different concentrations of CMPNeu5Ac in
the presence of increasing concentrations of the inhibitor CMP.
Reactions were analysed as previously described.
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Determination of NCAM, ST8SiaII and ST8SiaIV mRNA
expression by semi-quantitative RT-PCR analysis
Total RNA was isolated from the human cells SH-SY-5Y,
IMR-32, DLD-1 and rat glioma C6-STX and C6-WT cells using
RNeasy incorporating a DNase I step (Qiagen, West Sussex,
UK) according to the manufacturer’s instructions. Reverse
transcription was performed using the RevertAidTM H minus
First Strand cDNA synthesis kit (Fermentas) according to the
manufacturers recommendations with the primers described
below (Invitrogen). Primers were: hNCAM (sense) 5’-TGC CCA
TCC TCA AAT ACA AAG C-3’; hNCAM (antisense) 5’-ATC
AGG TTC ACT TTA ATA GAG TTT C-3’; rNCAM (sense) 5’-
TGC TCA AGT CCC TAG ACT GGA ACG-3’; rNCAM
(antisense) 5’-CTT CTC GGG CTC TGT CAG TGG TG-3’;
ST8SiaII (sense) 5’-CAG AGA TCG AAG AAG AAA TCG
GG-3’; ST8SiaII (antisense) 5’-GTG CTT ATT CTT CTT CAG
TGG CG-3’; ST8SiaIV (sense) 5’-CTA CAT AGC CTC CTA
CCT GAA G-3’; ST8SiaIV (antisense) 5’-GGA CAC TGT CAT
TCA GCA TGG-3’; GAPDH (sense) 5’-GGC CAA GGT CAT
CCA TGA-3’; GAPDH (antisense) 5’-TCA GTG TAG CCC AGG
ATG-3’. PCR amplification: initial denaturation at 94° C for 3
min followed by 22 (GAPDH), 30 (NCAM) or 35 (ST8SiaII and
ST8SiaIV) cycles of 94° C for 30 sec, 56° C for 30 sec and 72°
C for 45 sec. All cycles were terminated with a 5 min incubation
at 72° C to ensure complete elongation prior to incubation and
storage at 4° C. RT-PCR products were separated through a
agarose gel (1% w/v) and scanned on a Molecular Imager Fx
(BioRad, Dorset, UK) using Quantity One (v 4.6.5) software.
Western blotting for PolySia-NCAM
Cells were lysed on ice with extraction buffer, containing
Tris-HCl (50 mM, pH 8.0), NaCl (150 mM), EDTA (2.5 mM),
Triton-X-100 (1%), and 1 x protease inhibitor cocktail (Sigma)
for 60 min. The resulting lysate was centrifuged at 2000 g for
15 min at 4° C, and the concentration of the protein
concentration in the supernatant determined by Bradford
assay. Samples were resolved on 6% (50 µg, polySia) and
12% (25 µg, β-actin) polyacrylamide gels and blotted onto
Figure 1.  CMP is an inhibitor of ST8SiaII in vitro.  A: Activity of human ST8SiaII with increasing concentrations of DMB-DP3
acceptor over 5 hours, as measured by HPLC. B: Lineweaver-Burk plot* generated from A.Km of DMB-DP3 for ST8SiaII (derived
from x axis intercept) was calculated as 38.9 µM. Data points are from a single determination representative of two independent
experiments. C: HPLC trace extract showing that CMP (250 µM) inhibits polysialylation of DMB-DP3 (10 µM) to DMB-DP4 (ST8SiaII
250 ng; CMP-Neu5Ac 500 µM; 4 h; 25° C). D: Dixon Plot* indicating that CMP is a competitive inhibitor of ST8SiaII, Ki = 10 µM
(*Data points are from a single determination representative of two independent experiments).
doi: 10.1371/journal.pone.0073366.g001
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nitrocellulose membranes (Amersham). Non-specific antibody
binding was blocked via incubation in ECL blocking reagent
(5%, Amersham) and the blot was probed with either anti-
polySia antibody (1:3000 dilution) or mouse anti-β-actin (1:10
000 dilution; Sigma) overnight at 4° C. Antibody reactivity was
detected by horseradish peroxidase (HRP)-conjugated
antibody and chemiluminescence using ECL-Plus (Amersham).
Quantification of cell surface polySia-NCAM by flow
cytometry
Once cells had reached approximately 70% confluency, they
were treated with CMP for 24 hours and then detached to
produce single cell suspension. Cells were then centrifuged for
5 minutes at 400 g and pellets were re-suspended in HBSS/
medium (5 mL, 2% FCS). After spinning for 5 minutes at 400 g,
cells were fixed with of 70% ice cold ethanol (1 mL) in PBS at
-20° C for 30 minutes followed by addition of PBS (0.5 mL).
Cells were then centrifuged at 400 g for 5 minutes and the
ethanol/PBS layers were removed. Cell pellets were re-
suspended in EndoNA2-eGFP (75 µL, 10 µg/mL) for 60
minutes in darkness. After centrifugation for 5 minutes at 400 g,
cells were washed twice with PBS to remove excess EndoNA2-
eGFP followed by centrifugation for 5 minutes at 400 g. Cell
pellets were re-suspended in PBS (500 µL) and samples were
analysed using a BD FACSCalibur flow cytometer, using
Cellquest™ software (Becton Dickinson, Oxford, UK). At least
10,000 events were analysed per sample. All steps were
performed at room temperature unless otherwise stated.
PolySia-NCAM recovery assay
Cells were seeded at 1 x 104 cells/mL onto autoclaved cover
slips in a six-well plate in medium (2 mL) and incubated
overnight at 37° C in a 5% CO2 humidified atmosphere. Once
cells had adhered to cover slips, they were treated with EndoN
(0.5 µg/ml) for (24 hours), followed by two washes in HBSS. As
controls, cultures were fixed directly following EndoN treatment
to confirm polySia removal. Cultures were then incubated with
medium containing CMP at different concentrations for 6 hours.
Following these treatments, the cultures were rinsed twice with
HBSS and fixed with ice cold methanol at -20° C for 30
minutes. After air drying, they were stored at -20° C or
immediately processed for immunocytochemistry. Also, to
confirm polySia recovery, cultures were incubated with
inhibitor-free medium for the same time periods as for the CMP
treatments. The resulting slides were analysed by counting the
number of polySia-expressing cells. Results were expressed as
migration relative to the untreated control and as the mean ±
SD of three independent experiments. A Leica DMRB
microscope was utilised, with digital images captured by a
Leica MPS52 camera and processed using the AcQuis image
capture system.
In vitro migration assays
Scratch assay [47]: Cells were seeded into six-well plates at
different concentrations, and plates were then incubated
overnight at 37° C in a 5% CO2 humidified atmosphere. Once a
confluent monolayer had formed, a straight wound of
approximately 1 cm in length was created in the centre of the
well using a sterile P200 pipette tip. After scratching, the media
was slowly aspirated and discarded, and wells were washed
Figure 2.  Semi-quantitative PCR showing expression of polySTs and NCAM and Western blotting showing expression of
polySia-NCAM in cell lines.  A: C6-STX cells express ST8SiaII and NCAM, whereas C6-WT cells express NCAM only. B: SH-
SY5Y and IMR-32 cells both express ST8SiaII and NCAM. Expression of ST8SiaIV was not detected in SH-SY5Y cells, and was
barely detectable in IMR-32 cells. DLD-1 cells do not express NCAM or ST8SiaII. C: C6-STX, SH-SY5Y and IMR-32 cells all
express polySia, whereas C6-WT and DLD-1 cells do not.
doi: 10.1371/journal.pone.0073366.g002
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with growth medium (1 mL) to remove debris and smooth the
edge of the scratch. After washing with HBSS, fresh medium
was added to the cells with or without compound. The plates
were then incubated at 37° C in 5% CO2 for up to 24 hours.
During incubation, plates were periodically monitored using
phase-contrast microscopy to determine the time required for
the migrating cells to fully close the wound. Measurement of
the wound was achieved by measuring the gap width at five
points in the centre of the wound using an eyepiece graticule
with a micrometer scale. After 24 hours, cells were washed
twice with Hanks Balanced Salt Solution (HBSS) and fixed with
ice cold methanol at -20° C for 30 minutes. After fixation, cells
were then hydrated with two washes in PBS and counter-
stained with Harris’s Haematoxylin solution. They were then
washed briefly under running tap water, before the excess
water was drained for 1 minute and the plates left to dry at
room temperature. The resulting plates were viewed under a
Nikon dissecting microscope (Nikon, C-D55230, Japan) and
digital images were acquired for each sample. The extent of
cell migration, expressed as percentage migration, was
calculated as follows:
Figure 3.  Effect of ST8SiaII inhibition on cell surface polySia expression.  Upper: Flow cytometry analysis of effect of 24h
exposure to increasing CMP concentrations on polySia expression in IMR-32 cells (NCAM +; ST8SiaII +; polySia +). Lower: Relative
mean fluorescence intensities as a result of CMP treatment. Cells were labelled with EndoNA2-eGFP and analysed by flow
cytometry. Fluorescence is expressed as a mean percentage of that observed with the control (untreated cells) ± SD of three
independent experiments (* P < 0.01, ** P < 0.001). CMP causes a significant and concentration-dependent reduction in polySia
expression in IMR-32 cells.
doi: 10.1371/journal.pone.0073366.g003
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Migration (%) = ([Average of S0 - Average of S1] / Average
S1) × 100%, Where S0: is the width of initial perimeter; S1: is the
width of wound at time of sampling. Data were expressed as
means ± S.D of three independent experiments.
Cell exclusion-zone assay [48]. Cell seeding stoppers from
the Oris Cell Migration Assay Kit (Platypus Technologies,
Madison, USA) were inserted into each well of a 96-well plate
where they formed a tight seal to the base of the plate. Cells
were then seeded at a range of concentrations by adding cell
suspension (100 µL). The microplate was then incubated at 37°
C in a humidified atmosphere of 5% CO2 overnight to allow for
cell adherence. Once a confluent monolayer had formed
around the inserts, the stoppers were gently removed followed
by careful washing with HBSS to remove any detached cells.
For pre-migration controls (t0), the stoppers were left in the
wells until the day of fixation. After washing, fresh medium (100
µL) was added to the wells followed by incubation at 37° C in a
5% CO2 humidified atmosphere for up to 72 hours to allow cell
migration. Where required, CMP at varying concentrations was
added to the medium. During incubation, plates were
periodically monitored using phase-contrast microscopy to
examine the progression of cell migration. After re-population
of the detection zone, stoppers were removed from the controls
(pre-migration t0) and all cultures were rinsed twice with HBSS
and fixed with ice cold methanol at -20° C for 30 minutes. After
fixation, cells were then hydrated by two washes in PBS and
counterstained with Harris’ Haematoxylin solution as above.
The resulting plates were viewed under a Nikon dissecting
Figure 4.  Effect of ST8SiaII inhibition on recovery of polySia expression following removal by endoN.  C6-STX cells (left)
and SH-SY5Y cells (right) immunolabelled with anti-polySia antibody (mAb 735) followed by incubation with TRITC-conjugated
secondary antibody [PolySia orange; nuclei stained blue with DAPI]. (a) Negative control (absence of mAb 735); (b) Positive control
(absence of endoN/CMP treatment) (c) Removal of polySia with EndoN (0.3 µg/mL); (d) PolySia recovery following 6 h incubation in
absence of CMP; (e) PolySia recovery following 6 h incubation with CMP at 0.5 mM; (f) PolySia recovery following 6 h incubation
with CMP at 5 mM. CMP clearly prevents the recovery of polySia on the cell surface following biological removal at 5 mM. Scale bar
= 50 µm.
doi: 10.1371/journal.pone.0073366.g004
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microscope (Nikon, C-D55230, Japan) and digital images were
acquired for each sample. The images were analysed by
counting the empty spaces in the detection zone using a 432
point grid. Percentage migration was calculated as follows:
Migration (%) = ([Average of S0 - Average of S1] / Average of
S0) × 100%, where S0: numbers of empty grid spaces in the
detection zone at pre-migration t0; S1: number of empty grid
spaces in the detection zone at t1 (post-migration). Data were
expressed as mean ± S.D of three independent experiments.
Results
CMP is a competitive inhibitor of ST8SiaII
Using NCAM, in the presence of recombinant human
ST8SiaII and CMP-Neu5Ac (the substrate for polysialylation
reactions), CMP (1 mM) was shown to abolish polysialylation
(Figure S1). We then quantified this CMP inhibition employing
a 1,2-diamino-4,5-methylenedioxy-benzene (DMB)-labelled
trimer of α-2,8-linked sialic acid (DMB–DP3; where DP refers to
degree of polymerisation) as an alternative acceptor for
polysialylation in place of NCAM [45,49]. As a novel HPLC-
based assay, this is a significant improvement on previously
published methods, which indirectly measure inhibition via
quantification of nucleoside release from CMP-Neu5Ac
following the sialylation reaction [50,51].
Human ST8SiaII polysialylated DMB-DP3 (Km = 38.9 µM,
Figure 1) to DMB-DP4 as the major product, with
polysialylation up to DMB-DP7 also observed. At shorter
reaction times (4 h) DMB-DP4 was the only product, providing
the opportunity for a single peak from which to quantify product
concentrations in the presence of potential inhibitors. CMP was
shown to inhibit production of DMB-DP4 in a reproducible
manner (Figure 1). The activity of ST8SiaII (as measured by
DMB-DP4 product formation) was assessed in the presence of
varying concentrations of substrate (CMP-Neu5Ac) at each of
three CMP concentrations, while the quantity of DMB-DP3
acceptor was maintained at a constant level. CMP was
confirmed as a competitive inhibitor of ST8SiaII (Ki = 10 µM,
Figure 1).
CMP inhibits ST8SiaII-mediated tumour cell
polysialylation
We subsequently investigated whether ST8SiaII inhibition by
CMP results in modulation of cell-surface polySia of tumour
cells. We utilised isogenic C6 rat glioma cells, engineered to
over-express ST8SiaII (C6-STX cells) and associated polySia
[36]. Wild type (C6-WT) cells express NCAM, but not ST8SiaII
and are thus polySia-negative. The mRNA expression of
ST8SiaII and NCAM in transfected cell lines was confirmed by
semi-quantitative PCR, while polySia and NCAM expression
was established by western blot (Figure 2). Antibodies to
ST8SiaII are not available, but previous studies have indicated
that presence of polySia directly correlates with polyST
expression [28]. We additionally evaluated polySia-expressing
neuroblastoma cell lines SH-SY5Y and IMR-32. Both these
human cell lines predominantly express ST8SiaII and in both
cell lines NCAM is quantitatively polysialylated. We also
screened for the presence of ST8SiaIV mRNA, but in
accordance with literature data, SH-SY5Y cells did not express
ST8SiaIV and mRNA was barely detectable in IMR-32 cells
[28]. DLD-1 (colorectal adenocarcinoma) cells were selected as
a negative control, as these cells did not express ST8SiaII,
NCAM or polySia (Figure 2).
Two methods were employed to assess the effects of
ST8SiaII inhibition on tumour cell polySia expression. The first
method involved co-incubation of cells with CMP and
measuring its effect on polySia surface-expression using flow
cytometric analysis of endoNA2-eGFP, a highly specific
polySia antibody-mimetic [52]. Using this method we showed
that CMP inhibits NCAM polysialylation in a concentration-
dependent manner in IMR-32 cells (Figure 3).
The second method employed ablation of polySia expression
using endoN [53] and monitoring re-expression (recovery) in
the presence of CMP. In untreated C6-STX and SH-SY5Y cells
polySia expression was restored within 6 h, whereas cells
treated with CMP showed a persistent absence of polySia
(Figure 4). Similar results were observed with IMR-32 cells
(Figure S2). No cytotoxicity was observed for any of the cell
lines employed. Indeed, it was not possible to obtain an IC50
value from an MTT assay following 96 h exposure: CMP
showed no cytotoxicity at 10 mM, the highest concentration
examined.
CMP inhibits tumour cell migration in ST8SiaII-
expressing cells
Following the demonstration that ST8SiaII inhibition by CMP
leads to a concentration-dependent reduction of tumour cell-
surface polySia, we investigated whether the CMP-induced
inhibition of polySia expression impacted tumour cell migration.
To generally document that polySia expression drives cell
migration we used the rat glioma model C6, in which C6-STX
cells stably express ST8SiaII [36]. Their migratory capacity was
evaluated in 2D cell migration assays, specifically: (i) a
‘scratch’ assay and (ii) a cell exclusion-zone assay. C6-STX
cells migrate significantly faster than C6-WT cells in 2D cell
migration assays, as evidenced by the relative rates of wound
closure over a 24 h timeframe (Figure 5). These effects were
confirmed by biologically removing polySia from the cell
surface of C6-STX cells using endoN, which resulted in a
significant reduction in cell migration (Figure S3), while no
effect was visible on polySia-negative C6-WT and DLD-1 cells.
Using 2D cell migration assays we demonstrated that CMP
causes a significant reduction in the migration of ST8SiaII-
expressing C6-STX and SH-SY5Y cells (24 h exposure, Figure
5). CMP had no effect on the migration of C6-WT (negative for
ST8SiaII and polySia) or DLD-1 cells (negative for ST8SiaII,
NCAM and polySia). No cytotoxicity was observed in any of the
cell lines at the concentrations of CMP found to inhibit tumour
cell migration.
Discussion
The results of this study have shown for the first time that a
small molecule (CMP) can modulate tumour cell migration
through inhibition of polysialyltransferase ST8SiaII. The
enzyme ST8SiaII was the focus for these studies, reflecting the
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Figure 5.  Effect of ST8SiaII inhibition on tumour cell migration.  Effect of CMP treatment on the migration of C6-STX, C6-WT,
SH-SY5Y, and DLD-1 cells as assessed by 2D migration assays. Confluent cell monolayers were incubated with fresh complete
medium and re-population of scratched wounds after 24 h was assessed. Migration is expressed as a percentage of that observed
with untreated cells for a given cell line (complete re-population). CMP treatment at all concentrations decreased the migration
capacity of polySia-expressing SH-SY5Y and C6-STX cells in a concentration dependent manner. However, CMP treatment had no
significant effect on the migration of C6-WT and DLD-1 cells even at high concentrations. C6-WT and DLD-1 cells do not express
polySTs or polySia. Values shown are means ± S.D based on three independent experiments (* P < 0.01).
doi: 10.1371/journal.pone.0073366.g005
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understanding that of the two polySTs, it is ST8SiaII that acts
as the major driver of polysialylation, and the associated
conversion from an adhesive to a metastatic phenotype in
tumour cells [24]. ST8SiaII gene expression has been shown to
dramatically increase during tumour cell progression, whereas
ST8SiaIV levels remain very low [54]. ST8SiaII has also been
observed to regulate polySia expression in SCLC cells [55],
and gene expression of ST8SiaII in neuroblastoma samples
strongly correlates with stage and grade of disease and is
highly prognostic of poor patient outcome [56,57]. .
Additionally, oncogenic transcription factor Pax3 is closely
involved in the regulation of ST8SiaII in tumour cells:
engineered over-expression of this gene is known to increase
ST8SiaII mRNA levels by up to four-fold, whereas ST8SiaIV
mRNA is not affected [58].
We have demonstrated that CMP is a competitive ST8SiaII
inhibitor, albeit with low potency, and that it modulates polySia-
mediated tumour cell migration. The high (mM) concentrations
of CMP required to inhibit ST8SiaII and tumour cell migration
are likely to be due to the hydrophilic/lipophilic balance of the
molecule limiting membrane permeability. However, our cell-
based studies indicate that CMP is sufficiently lipophilic to
reach the Golgi-localised ST8SiaII [59]. It is possible that
ST8SiaII inhibition by CMP is rate-limited by its transport into
the Golgi apparatus [44].
Glioma cells are highly invasive and migratory in vivo by a
process shown to be dependent on polySia [36] and our
studies are consistent with a role for polySia in migration of
NCAM-polySia expressing tumour cells. We previously
demonstrated that following injection into the brain, C6-STX
cells (but not C6-WT cells) invaded the corpus callosum [36].
Our present results demonstrate that C6-STX cells migrate
faster than C6-WT cells in vitro and thus represent a useful
model to assess the anti-migratory effects of polyST inhibitors.
ST8SiaII knockdown by siRNA [38] or biological removal of
polySia by endoN [37,60] both indicate that ST8SiaII-mediated
polySia biosynthesis is crucial for migration in polySia-
expressing tumour cells, further demonstrating the significance
of this target.
The precise molecular events by which polySia and NCAM
modulate cell adhesion, migration and invasion have yet to be
elucidated. However, key to the potential modulating effects of
polySia is the impact on the homophilic and heterophilic
interactions of NCAM and the complex network of intracellular
signalling activated upon binding [61]. For example, polySia is
known to potentiate signal transduction via FGFR and focal
adhesion kinase (FAK) signalling, which in turn affects Fyn,
ERK and other downstream events [62–65]. PolySia-NCAM
signalling through FAK and involving both Ras-MAPK and
FGFR-PLCγ-PKC has also been demonstrated [66] and a role
has additionally been elucidated for the PI3K/Akt pathway in
NCAM-mediated cell survival [67]. NCAM is additionally known
to interact with several extracellular matrix components,
including heparin, collagen, cadherins, a number of chondroitin
sulfate and heparan sulfate proteoglycans [68–70]. PolySia and
NCAM thus regulate cell-cell and cell-substrate interactions.
Important in this context is that both factors have global effects
on cellular recognition processes and signalling events that
elicit changes in tumour cell behaviour beyond the direct
involvement of, for example, NCAM-mediated adhesion
[24,66].
Here we have shown that CMP is essentially non-toxic to
cells and yet has anti-migratory activity. The question remains
as to whether it is possible for a small molecule ST8SiaII
inhibitor to significantly reduce tumour cell invasion and
metastasis, through modulation of polySia expression.
In conclusion, these results demonstrate that CMP is a
competitive small molecule ST8SiaII inhibitor and that the
resultant ablation of tumour cell-surface polySia expression
correlates with a significant diminution in tumour cell migration.
Furthermore, we have identified a link between
pharmacological suppression of ST8SiaII activity and tumour
cell migration and have thus shown that ST8SiaII is a
druggable target.
The challenge ahead is to develop a potent, selective small
molecule ST8SiaII inhibitor and to ultimately demonstrate
efficacy in vivo. Given that metastatic spread of tumour cells is
such a progressive and multifactorial process [71], and that it
remains the major cause of morbidity and mortality in cancer
[72], it is clear that new approaches to therapy are vital: there
are currently no anti-metastatic agents available for treatment.
We firmly believe that this study has finally unlocked the
potential for inhibition of ST8SiaII as an exciting and
desperately needed therapeutic opportunity for metastatic
cancer. We are currently investigating small molecules based
on CMP to identify more potent inhibitors of ST8SiaII with
benefit in preventing dissemination of polySia-expressing
tumours.
Supporting Information
Figure S1.  ST8SiaII inhibition by CMP inhibits
polysialylation in an in vitro assay. Expression of polySia
following incubation of NCAM (50 ng), ST8SiaII (250 ng), CMP-
Neu5Ac (200 µM) and increasing concentrations of CMP (as
indicated). Reactions were pre-incubated for 5 mins, after
which CMP-Neu5Ac was added to initiate the reactions.
Incubation time: 30 min at 37° C, in presence of MgCl2 (5 mM)
in MES buffer (50 mM; pH 7); total vol. 20 µL. Polysialylation is
completely inhibited in presence of 1 mM CMP.
(TIFF)
Figure S2.  Effect of ST8SiaII inhibition on recovery of
polySia expression following removal by EndoN in IMR-32
cells. IMR-32 cells immunolabelled with anti-polySia antibody
(mAb 735) followed by incubation with TRITC-conjugated
secondary antibody. (a) Negative control (absence of mAb
735); (b) Positive control (absence of endoN/CMP treatment)
(c) Removal of polySia with EndoN (0.3 µg/mL); (d) PolySia
recovery following 24 h incubation in absence of CMP; (e)
PolySia recovery following 24 h incubation with CMP at 0.5
mM; (f) PolySia recovery following 24 h incubation with CMP at
5 mM. CMP clearly prevents the recovery of polySia on the cell
surface following biological removal at 5 mM.
(TIFF)
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Figure S3.  Effect of biological removal of polySia on
tumor cell migration. Migration of C6-STX, C6-WT and DLD-1
cells was assessed. Confluent cell monolayers were incubated
with fresh complete medium and repopulation of exclusion
zones was assessed after 60 h for C6-STX cells, 72 h for C6-
WT cells and 120 h for DLD-1 cells. EndoNF treatment of C6-
STX cells led to a highly significant reduction in cell migration
(17% of control, P<0.01), but no effect on C6-WT or DLD-1
cells.
(TIFF)
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